Skin Cancer Treatment Insurance Claim Denied? How to Appeal

Skin cancer is the most commonly diagnosed cancer in the United States, with over 5 million cases treated annually. Treatment options range from simple excision of basal cell or squamous cell carcinoma to complex multimodal regimens for melanoma including surgery, immunotherapy (pembrolizumab, nivolumab, ipilimumab), targeted therapy (BRAF/MEK inhibitors), and radiation. Insurance denials occur across the spectrum — from adjudication of "cosmetic" excision to Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization denials for immunotherapy. Knowing your rights makes the difference between a manageable dispute and a delayed or foregone treatment.

Why Insurers Deny Skin Cancer Treatment

Procedure classified as cosmetic. Insurers occasionally label skin cancer excision — particularly for basal cell and squamous cell carcinoma — as cosmetic when the location involves the face or visible skin areas. This classification is factually incorrect: removal of a malignant or premalignant lesion is a medical necessity regardless of location. ACA essential health benefits require coverage of cancer treatment, and no legitimate clinical guideline supports characterizing malignant lesion removal as cosmetic.

Immunotherapy or targeted therapy denied as not medically necessary. For advanced melanoma, insurers frequently require prior authorization for FDA-approved agents including pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), and BRAF/MEK inhibitor combinations. Denials cite insufficient staging documentation, alternative treatment not exhausted, or criteria more restrictive than NCCN guidelines.

Mohs surgery denied as not medically necessary or excessive. Mohs micrographic surgery — the gold standard for high-risk basal cell and squamous cell carcinoma with specific anatomic location or histologic features — is frequently denied in favor of simple excision. The insurer may argue Mohs is not the least costly effective treatment despite the American College of Mohs Surgery (ACMS) criteria establishing clear indications where Mohs provides superior outcomes with less tissue sacrifice.

Step therapy requirements for advanced melanoma systemic therapy. Some plans require patients to have tried and failed one immunotherapy agent before approving combination regimens or alternative checkpoint inhibitors. For patients whose disease characteristics indicate a specific treatment approach, these requirements may be clinically inappropriate and appealable under NCCN guideline support.

Experimental or investigational designation for newer agents. Newer checkpoint inhibitors, combination regimens, or adjuvant treatment approaches may be labeled experimental despite FDA approval or NCCN Category 1 guideline designation.

How to Appeal a Skin Cancer Treatment Denial

Step 1: Obtain the Denial Details and Clinical Criteria

Request the denial letter with the specific policy provision or clinical criterion applied, and the complete claims file including the reviewing physician's notes and clinical policy bulletin. Identify whether the denial is a medical necessity determination, an experimental designation, a step therapy issue, or a cosmetic classification.

Step 2: Document Pathology, Staging, and Clinical Characteristics

Your appeal must include complete pathology documentation: biopsy report with histologic diagnosis, tumor type (BCC, SCC, melanoma), Breslow depth and Clark level for melanoma, presence of ulceration, mitotic rate, lymphovascular invasion, and any sentinel lymph node biopsy results. For advanced disease, include imaging documenting staging (CT, PET-CT, MRI) and documentation of BRAF mutation status for melanoma patients.

Step 3: Cite NCCN Clinical Practice Guidelines

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology are the gold standard for cancer treatment coverage determinations. For melanoma, Merkel cell carcinoma, and high-risk keratinocyte carcinomas, NCCN Guidelines provide specific, evidence-based treatment recommendations by disease stage and patient characteristics. Most major insurers commit to covering NCCN Category 1 recommended treatments. If your treatment has NCCN Category 1 or 2A designation, cite this explicitly in your appeal.

Step 4: For Mohs Surgery — Cite ACMS Appropriate Use Criteria

The American College of Mohs Surgery published Appropriate Use Criteria (AUC) for Mohs micrographic surgery that specify which tumor types, locations, and patient characteristics warrant Mohs over standard excision. If your tumor meets the AUC criteria — periorbital, perioral, periaural, nasal, or other high-risk anatomic location; aggressive histologic subtype; recurrent tumor — cite the AUC directly in your appeal.

Step 5: Secure an Oncology or Dermatology Letter of Medical Necessity

Your treating oncologist's or dermatologist's letter should document the diagnosis and staging, the treatment selected and its NCCN guideline support, why the chosen approach is the appropriate standard of care for your specific disease characteristics, and why any alternatives the insurer proposes are clinically inferior or inappropriate for your case.

Step 6: Submit the Appeal and Escalate if Needed

File the formal appeal within the applicable deadline (180 days for commercial plans). If denied, file for independent External Independent Review: Complete Guide" class="auto-link">external review under 45 CFR § 147.138. Request that the IRO assign an oncologist or dermatologist to review the case — a specialist reviewer is far more likely to recognize the clinical appropriateness of NCCN-guided treatment than a general medicine reviewer.

What to Include in Your Appeal

• Denial letter identifying the specific clinical criterion or policy provision cited
• Complete pathology report with all relevant histologic and prognostic features
• Staging documentation including imaging reports
• NCCN Clinical Practice Guidelines excerpt showing the specific recommendation for your stage and disease characteristics
• For Mohs surgery: ACMS Appropriate Use Criteria demonstrating that your tumor meets the indications
• Your oncologist's or dermatologist's letter of medical necessity
• FDA approval documentation for the specific agent or regimen if an experimental designation is challenged

Fight Back With ClaimBack

Skin cancer treatment denials involving NCCN-recommended therapies, FDA-approved immunotherapy, or established surgical approaches like Mohs are among the most defensible appeals in oncology. ClaimBack generates a professional appeal letter citing NCCN guidelines, ACMS criteria, and the specific clinical facts of your case. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal